Inovio Pharmaceuticals Inc. has reported its second quarter 2025 financial results, highlighting a reduction in total operating expenses to $23.1 million, down from $33.3 million during the same period in 2024. The net loss for the three months ending June 30, 2025, decreased to $23.5 million, or $0.61 per basic and diluted share, compared to a net loss of $32.2 million, or $1.19 per basic and diluted share, in the corresponding period of the previous year. Inovio is on track to submit a Biologics License Application $(BLA.AU)$ for INO-3107 in the second half of 2025, targeting file acceptance by year-end. The company has completed the design verification testing of the CELLECTRA® 5PSP device required for the BLA submission and is advancing commercial preparations for the potential launch of INO-3107 in 2026, pending FDA approval. The company estimates that its current cash, cash equivalents, and short-term investments will support operations into the second quarter of 2026. This projection includes an estimated operational net cash burn of approximately $22 million for the third quarter of 2025. Additionally, Inovio strengthened its balance sheet with a public offering in July 2025, raising approximately $22.5 million in net proceeds.